Publications by authors named "Prabhakaran Rathinam"
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
Clin Infect Dis
December 2024
Article Synopsis
- The study examined the effectiveness and safety of reducing linezolid doses in a treatment regimen for adults with pre-extensively drug-resistant or treatment-intolerant multidrug-resistant tuberculosis.
- Patients were enrolled in a clinical trial where they were randomly assigned to three different dosing regimens of linezolid, alongside bedaquiline and pretomanid, for a total duration of 26 weeks.
- Results showed that the reduced dose of linezolid (300 mg/day) maintained similar cure rates as the standard dose (600 mg/day) while leading to fewer reported cases of peripheral neuropathy, suggesting a safer approach for treating this condition.
Xpert MTB/RIF is recommended for the diagnosis of tuberculosis (TB) in children. We determined the performance of Xpert MTB/RIF in the diagnosis of pulmonary TB in children. The characteristics of children influencing Xpert MTB/RIF positivity were explored.
View Article and Find Full Text PDFIntroduction: COVID19* is a new disease with significant mortality risk. Because of the scarcity of the study on factors associated with the mortality in Tamil Nadu present study was done to determine the factors associated with the outcome of the COVID19 patients admitted in a tertiary care hospital, Madurai.
Methodology: 4530 lab confirmed COVID19 patients admitted from March to August 31st 2020; excluding the non-responders or who gave incomplete information were included in the study.
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Trop Med Int Health
April 2020
Background: Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India.
Methods: New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H R Z E /4R H ) [C].
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
JAMA Intern Med
April 2018
Importance: The benefit of daily over thrice-weekly antituberculosis therapy among HIV-positive patients with pulmonary tuberculosis (TB) who are receiving antiretroviral therapy remains unproven.
Objective: To compare the efficacy and safety of daily, part-daily, and intermittent antituberculosis therapy regimens in the treatment of HIV-associated pulmonary TB.
Design, Setting, And Participants: This open-label, randomized clinical trial was conducted by the National Institute for Research in Tuberculosis, south India.
Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Clin Infect Dis
November 2014
Background: Rapid sputum culture conversion at 2 months indicates the sterilizing capacity and potential of regimens to shorten duration of tuberculosis treatment. We compared results of sputum culture conversion by moxifloxacin and control regimens and identified factors affecting sputum culture positivity after 2 months of treatment.
Methods: Human immunodeficiency virus-uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- or 4-month moxifloxacin regimen (moxifloxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen (RHZE thrice weekly).